The page below is a sample from the LabCE course Tumor Markers. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Tumor Markers (online CE course) »
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 97 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Individual course$20 Add to cart

Prostate-Specific Antigen (PSA): Clinical Applications in Monitoring Recurrence

Patients in remission of prostate cancer, or following a radical prostatectomy, continue to be monitored on a prescribed basis using PSA.
As previously discussed, ANY detection of PSA in the blood of a patient who has had a radical prostatectomy is reason for concern and warrants more thorough investigation as to the source of the PSA production.
The increase of PSA level in a patient who has been previously successfully treated for prostate cancer is also a cause for concern, as it may indicate the resurgence or regrowth of a tumor, or may indicate that the benign tissues of the prostate are producing increased amounts of PSA due to infection, benign prostatic hyperplasia (BPH), or acute urinary retention due to an obstruction.
A great deal of time has been dedicated in this exercise to examining the utility of PSA, as it is one of the most widely studied, well-characterized, and analytically standardized tumor marker. Despite these facts, PSA still falls short of being the ideal tumor marker.